Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
1762
mi
from 91732
Nashville, TN
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Vaccine (VV) CRS
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
356
mi
from 91732
San Francisco, CA
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Bridge HIV CRS
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
2244
mi
from 91732
Rochester, NY
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
University of Rochester Vaccines to Prevent HIV Infection CRS
2244
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Mbeya,
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS
mi
from 91732
Mbeya,
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
2576
mi
from 91732
Boston, MA
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Fenway Health (FH) CRS
2576
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
963
mi
from 91732
Seattle, WA
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Seattle Vaccine and Prevention CRS
963
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
2576
mi
from 91732
Boston, MA
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
2576
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Penn Prevention Crs
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence
ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence
Status: Enrolling
Updated:  12/31/1969
1991
mi
from 91732
Chapel Hill, NC
ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence
ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence
Status: Enrolling
Updated: 12/31/1969
Clinical and Translational Research Center, UNC Hospitals
1991
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
1785
mi
from 91732
Birmingham, AL
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Alabama CRS
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
22
mi
from 91732
Torrance, CA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA CRS
22
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
825
mi
from 91732
Aurora, CO
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2578
mi
from 91732
Boston, MA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital CRS (MGH CRS)
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2422
mi
from 91732
Newark, NJ
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School Clinical Research Center CRS
2422
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2189
mi
from 91732
Chapel Hill, NC
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Chapel Hill CRS
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
3356
mi
from 91732
San Juan,
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
3356
mi
from 91732
San Juan,
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
1919
mi
from 91732
Atlanta, GA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2281
mi
from 91732
Washington,
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Whitman-Walker Health CRS
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
353
mi
from 91732
San Francisco, CA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Ucsf Hiv/Aids Crs
353
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
2153
mi
from 91732
Greensboro, NC
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS
2153
mi
from 91732
Greensboro, NC
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
21
mi
from 91732
Los Angeles, CA
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
21
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
1730
mi
from 91732
Chicago, IL
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated:  12/31/1969
1879
mi
from 91732
Cincinnati, OH
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Cincinnati Clinical Research Site
1879
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection
RISE: Real World Insights of People Living With HIV Shared Through Electronic Devices
Status: Enrolling
Updated:  12/31/1969
2275
mi
from 91732
Arlington, VA
Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection
RISE: Real World Insights of People Living With HIV Shared Through Electronic Devices
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2275
mi
from 91732
Arlington, VA
Click here to add this to my saved trials
Retention in HIV Care for Hispanic Immigrants
Addressing Barriers to Retention in HIV Care for Hispanic Immigrants
Status: Enrolling
Updated:  12/31/1969
2578
mi
from 91732
Boston, MA
Retention in HIV Care for Hispanic Immigrants
Addressing Barriers to Retention in HIV Care for Hispanic Immigrants
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Zaleplon in HIV Patients With Depression
A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Zaleplon in HIV Patients With Depression
A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression
Status: Enrolling
Updated: 12/31/1969
Mood & Anxiety Disorders Research and Treatment Program
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)
Status: Enrolling
Updated:  12/31/1969
2441
mi
from 91732
Bronx, NY
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)
Status: Enrolling
Updated: 12/31/1969
Albert Einstein College of Medicine
2441
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Nairobi,
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)
Status: Enrolling
Updated: 12/31/1969
Kenya Medical Research Institute, Partners in Prevention, University of Nairobi
mi
from 91732
Nairobi,
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated:  12/31/1969
1785
mi
from 91732
Birmingham, AL
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated: 12/31/1969
Alabama CRS
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated:  12/31/1969
2121
mi
from 91732
Pittsburgh, PA
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh CRS
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults
A Phase 1b Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adult Participants
Status: Enrolling
Updated:  12/31/1969
356
mi
from 91732
San Francisco, CA
Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults
A Phase 1b Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adult Participants
Status: Enrolling
Updated: 12/31/1969
Bridge HIV CRS
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue
Feasibility and Acceptability of an mHealth Cognitive Behavioral Stress Management Intervention to Ameliorate HIV-related Fatigue
Status: Enrolling
Updated:  12/31/1969
2184
mi
from 91732
Charleston, SC
CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue
Feasibility and Acceptability of an mHealth Cognitive Behavioral Stress Management Intervention to Ameliorate HIV-related Fatigue
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing
Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing
Status: Enrolling
Updated:  12/31/1969
2563
mi
from 91732
Providence, RI
Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing
Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing
Status: Enrolling
Updated: 12/31/1969
Brown University School of Public Health
2563
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
1333
mi
from 91732
Overland Park, KA
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1333
mi
from 91732
Overland Park, KA
Click here to add this to my saved trials
Advanced HIV Prevention (PrEP Chicago)
Advanced HIV Prevention (PrEP Chicago)
Status: Enrolling
Updated:  12/31/1969
1730
mi
from 91732
Chicago, IL
Advanced HIV Prevention (PrEP Chicago)
Advanced HIV Prevention (PrEP Chicago)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
1211
mi
from 91732
Austin, TX
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1211
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Impact of Screening Patients With HIV for Kidney Disease
Impact of Screening Patients With HIV for Kidney Disease
Status: Enrolling
Updated:  12/31/1969
1609
mi
from 91732
Jackson, MS
Impact of Screening Patients With HIV for Kidney Disease
Impact of Screening Patients With HIV for Kidney Disease
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
1609
mi
from 91732
Jackson, MS
Click here to add this to my saved trials
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
2119
mi
from 91732
Saint Petersburg, FL
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
University of South Florida
2119
mi
from 91732
Saint Petersburg, FL
Click here to add this to my saved trials
Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders
Neuroimaging Correlates of Monocyte/Macrophage Infiltration in HIV-infected Individuals: A Cross-sectional Pilot Study Using IV Ferumoxytol
Status: Enrolling
Updated:  12/31/1969
2570
mi
from 91732
Honolulu, HI
Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders
Neuroimaging Correlates of Monocyte/Macrophage Infiltration in HIV-infected Individuals: A Cross-sectional Pilot Study Using IV Ferumoxytol
Status: Enrolling
Updated: 12/31/1969
Hawaii Center for AIDS
2570
mi
from 91732
Honolulu, HI
Click here to add this to my saved trials
Group Clinical Visit Adherence Intervention for HIV+ Women of Color
Development and Testing of a Group Clinical Visit Adherence Intervention for HIV+ Women of Color
Status: Enrolling
Updated:  12/31/1969
2438
mi
from 91732
Bronx, NY
Group Clinical Visit Adherence Intervention for HIV+ Women of Color
Development and Testing of a Group Clinical Visit Adherence Intervention for HIV+ Women of Color
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
2438
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
ARV Concentrations in Hair
IGHID 11601 - Measuring Antiretroviral Concentrations in Hair
Status: Enrolling
Updated:  12/31/1969
2189
mi
from 91732
Chapel Hill, NC
ARV Concentrations in Hair
IGHID 11601 - Measuring Antiretroviral Concentrations in Hair
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated:  12/31/1969
2121
mi
from 91732
Pittsburgh, PA
Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh CRS
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of an HIV Outreach Program
Evaluation of an Outreach and Intervention Program to Reach HIV- Positive Persons Living in Bronx, NY Single Room Occupancy Hotels
Status: Enrolling
Updated:  12/31/1969
2438
mi
from 91732
Bronx, NY
Evaluation of an HIV Outreach Program
Evaluation of an Outreach and Intervention Program to Reach HIV- Positive Persons Living in Bronx, NY Single Room Occupancy Hotels
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
2438
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Cultural Adaptation and Piloting of a Smoking Cessation Intervention for Smokers With HIV
Cultural Adaptation and Piloting of an Avatar Delivered Smoking Cessation Intervention for Low Income Smokers in Baltimore City Living With HIV
Status: Enrolling
Updated:  12/31/1969
2301
mi
from 91732
Baltimore, MD
Cultural Adaptation and Piloting of a Smoking Cessation Intervention for Smokers With HIV
Cultural Adaptation and Piloting of an Avatar Delivered Smoking Cessation Intervention for Low Income Smokers in Baltimore City Living With HIV
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
2281
mi
from 91732
Washington,
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
George Washington University Medical Faculty Associates
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC
Status: Enrolling
Updated:  12/31/1969
2281
mi
from 91732
Washington,
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC
Status: Enrolling
Updated: 12/31/1969
Howard University
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women
DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women
Status: Enrolling
Updated:  12/31/1969
2204
mi
from 91732
Research Triangle Park, NC
Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women
DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2204
mi
from 91732
Research Triangle Park, NC
Click here to add this to my saved trials
Engagement in HIV Primary Care Services
Determinants of Engagement in HIV Primary Care Services Among Black and Hispanic Single Room Occupancy Hotel Residents in New York City
Status: Enrolling
Updated:  12/31/1969
2438
mi
from 91732
Bronx, NY
Engagement in HIV Primary Care Services
Determinants of Engagement in HIV Primary Care Services Among Black and Hispanic Single Room Occupancy Hotel Residents in New York City
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
2438
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
San Antonio, TX
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated: 12/31/1969
ILEX Oncology Inc
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials